Our Research

Pipeline

 

Pipeline

We are a research-driven biotech company dedicated to the discovery of first-in-class therapies addressing unmet needs. Our platforms and portfolio deliver NCEs and protein therapeutics against novel targets of relevance in oncology and neurodegeneration.

Hit Finding

Hit to Lead

Lead Optimzation

Preclinical Development

Clinical Development

WEE-1 inhibitor

Oncology

ALM301

Partnered

Partnered DUB Target

Multiple DUB Targets

Various TA

ROR1 VNAR-Drug Conjugates

Oncology

Target 2, Target 3

Ubi-Plex® Platform (Protein Homeostatasis)

Protein Therapeutics Platform

Research Pipelines

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies